Consensus EPS · Q2 2026
$6.79
Consensus revenue · Q2 2026
$20.6B
Analysts
12
Expected report
Aug 5, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 12 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $20.1B | $20.6B | $21.6B |
| EPS | $5.28 | $6.79 | $9.08 |
| EBITDA | $6.3B | $6.6B | $6.8B |
| EBIT | $5.5B | $5.7B | $5.9B |
| Net income | $4.4B | $5.4B | $6.4B |
- Revenue$20.6B
- EPS$6.79
- EBITDA$6.6B
- EBIT$5.7B
- Net income$5.4B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $19.8B | $17.8B | +11.1% | $8.55 | $6.97 | +22.6% |
| Q4 2025 | $19.3B | $17.9B | +7.5% | $7.54 | $6.91 | +9.1% |
- Q1 2026+11.1%+22.6%
- Q4 2025+7.5%+9.1%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
| Metric | Now | 30d ago | 60d ago | 90d ago | 30d Δ |
|---|---|---|---|---|---|
| Revenue | $20.6B | $20.5B | — | — | +0.8% |
| EPS | $6.04 | $8.81 | — | — | -31.5% |
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Eli Lilly (LLY) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 9 analysts.
- Low
- $1,135.00
- Consensus
- $1,315.42
- Median
- $1,300.00
- High
- $1,500.00
- Current
- $1,163.01
- Upside
- +13.1%
Upside calculated vs most recent trading price of $1,163.01.
Analyst ratings
Consensus: Buy — based on 45 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 15, 2026 | Citigroup | maintain | Buy | Buy |
| Jul 14, 2026 | Bernstein | maintain | Outperform | Outperform |
| Jul 13, 2026 | UBS | maintain | Buy | Buy |
| Jul 13, 2026 | Guggenheim | maintain | Buy | Buy |
| Jul 10, 2026 | B of A Securities | maintain | Buy | Buy |
| Jul 8, 2026 | Truist Securities | maintain | Buy | Buy |
| Jul 8, 2026 | RBC Capital | maintain | Outperform | Outperform |
| Jul 8, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 7, 2026 | JP Morgan | maintain | Overweight | Overweight |
| Jul 6, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
- Jul 15, 2026CitigroupBuy
- Jul 14, 2026BernsteinOutperform
- Jul 13, 2026UBSBuy
- Jul 13, 2026GuggenheimBuy
- Jul 10, 2026B of A SecuritiesBuy
- Jul 8, 2026Truist SecuritiesBuy
- Jul 8, 2026RBC CapitalOutperform
- Jul 8, 2026Morgan StanleyOverweight
- Jul 7, 2026JP MorganOverweight
- Jul 6, 2026Cantor FitzgeraldOverweight
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.64% TTM
- Dividend Profile0.56% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History4 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.